CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan
TOKYO and BERLIN, Nov. 22, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben 18F injection) has been approved from the Ministry of Health, Labor, and Welfare to be reimbursed by governmental health insurance. With this C2 path approval, Neuraceq®-PET is the first amyloid PET diagnostic tool currently reimbursed in Japan. Neuraceq® is available in Japan from the approved medical device 放射性医薬品自動合成装置Synthera+ (PMDA medical device license no. 30100BZX0016900) and is currently accessible at Keio University Hospital, Tokyo, Koseikai Takeda Hospital, Kyoto and Uozumi Clinic, Kumamoto. CMI Inc. plans to set up Neuraceq® production at further hospital radiopharmacy sites.
- With this C2 path approval, Neuraceq®-PET is the first amyloid PET diagnostic tool currently reimbursed in Japan.
- Neuraceq® is available in Japan from the approved medical device 放射性医薬品自動合成装置Synthera+ (PMDA medical device license no.
- 30100BZX0016900) and is currently accessible at Keio University Hospital, Tokyo, Koseikai Takeda Hospital, Kyoto and Uozumi Clinic, Kumamoto.
- With the reimbursement of this diagnostic tool, Japanese physicians can use this state-of-the-art imaging technology to accurately evaluate their patients with cognitive decline.